Member Info for Laura2022

With advancements in technology, we're seeing a shift towards personalised dosing to improve individual patient benefit, and therapeutic drug monitoring is central to this approach. Check out this insightful feature article by our partner DoseMe. 👇

At Physiomics plc, we’re passionate about using data science and modelling techniques to enhance drug development and improve patient outcomes, which includes the development of new personalised medicine solutions.

We're excited to partner with DoseMe to integrate our personalised dosing software into the DoseMeRx platform. Together, we're making drug development smarter and more personalised, helping to get the right dose to the right patient.

Hi Time

Silly question, is this good news for IES .

Much better

Looks like the bottom is on charts and in terms of the business

9.7p to 9.9p

Did you read the Ambrose information that was re posted uncanny ?

Is in my view

IES

Outlook

 

Including the UKIB investment for UK projects, as at 30 June 2024, the Company had cash reserves of £49.2m. By maintaining strict capital discipline and a focus on targeted sales in 2025 as referenced above, the Company believes it will enter 2026 in a position to deliver Mistral at industry standard margins and an ever-growing production rate, together sufficient to achieve EBITDA breakeven and set the Company on a sustainable future.

 

 

Jonathan Marren, Chief Executive Officer at Invinity said:

 

"The development team, in collaboration with our joint development and commercialisation partner, have rightly focused on ensuring that Mistral is capable of delivering the performance characteristics being demanded by customers and the market; I am very pleased with the results to date. We aren't yet where we wanted to be on working through the identified initiatives aimed at reducing production costs to the level we believe we can attain but have confidence this can be achieved in 2025 ahead of material volumes at sustainable margins in 2026 and beyond.

 

Question

This was a good news RNS

Why has it not gone upwards please ?

Yes jim bob

Having seen the initial RNS and waited a while I have purchased the first 2 amounts

Any best ideas?

IES looks far too cheap and fallen far too far

There are 5 more II so will be interesting to see if they follow

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm the execution of a co-marketing agreement (the "Agreement") with US contract research organisation Netoids Rx Laboratories LLC, doing business as Spanios LLC ("Spanios"), to provide Inaphaea's high throughput drug screening services using its Patient Derived Cells ("PDC") as a precursor to Spanios's proprietary Patient Derived Tumoroid

That clears things up thanks Ray

I've noticed that many people have stronger options and clarity on shares they DON'T own

Porky being a prime example

So is that a yes or no Ray

I was happy with the email I got back from Mark regarding Val201 and Ambrose

Do I assume you don't hold then ?

See page 15

That's because it was specifically set up as an investment vehicle

They've now secured that

Maybe just spell out exactly what point you want to make as there's loads of filings

Any particular part ?